Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $55.50.

A number of equities analysts recently issued reports on the stock. BTIG Research reaffirmed a “buy” rating and set a $15.00 target price on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, Wall Street Zen lowered shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th.

Tvardi Therapeutics Trading Down 5.0%

Shares of TVRD stock opened at $3.22 on Tuesday. Tvardi Therapeutics has a 1 year low of $2.75 and a 1 year high of $43.65. The firm’s fifty day simple moving average is $3.52 and its 200 day simple moving average is $5.64. The firm has a market capitalization of $30.20 million, a P/E ratio of -0.58 and a beta of 0.16.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Tuesday, March 31st. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23). Equities research analysts anticipate that Tvardi Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Arax Advisory Partners increased its holdings in Tvardi Therapeutics by 277.2% in the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares during the period. JPMorgan Chase & Co. bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at $43,000. HRT Financial LP bought a new stake in Tvardi Therapeutics in the 4th quarter valued at $47,000. Finally, XTX Topco Ltd bought a new stake in Tvardi Therapeutics in the 4th quarter valued at $55,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.